No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Chemicals - Specialty
Kaneka Corporation, established in Tokyo, Japan, in 1949, operates internationally as a diversified manufacturer providing a wide array of advanced materials and specialized products. Its core chemical business includes the production and global distribution of various polyvinyl chloride (PVC) formulations, such as crosslinked, paste, and chlorinated PVC, alongside acryl grafted-vinyl chloride copolymers. The company also supplies critical additives like impact modifiers, processing aids, specialty additives, and tougheners for thermosetting resins. Furthermore, their portfolio features advanced polymers including silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, biodegradable polymers, and engineering resins designed for injection molding, in addition to zero birefringence materials, acrylic films, and isobutylene-based thermoplastic elastomers. Beyond chemicals, Kaneka manufactures specialized foams and films, encompassing polypropylene and Kanelite foams, extruded polystyrene insulation, polyimide films, and transparent films for optical applications. Their material science expertise extends to high thermal conductive graphite sheets, multi-layer insulation, transparent conductive films, and transparent resins engineered for exceptional heat and light resistance. In the energy and innovative products sector, Kaneka offers photovoltaic power generation systems suitable for residential, public, and industrial installations. Other cutting-edge developments include eco-friendly fur, flame-retardant materials, hair accessories, novel materials, organic EL lighting panels, and biosurfactants. Their life sciences division delivers a comprehensive range of medical and pharmaceutical offerings, which include intervention and blood purification systems, gastroenterology intervention tools, diagnostic testing equipment, regenerative medicine and cell therapy solutions, and genetic diagnostics. Additionally, they provide low molecular pharmaceutical raw materials, affinity chromatography resins for monoclonal antibody purification, biopharmaceuticals, transdermal medicines, and innovative shock-absorbing innerwear. Lastly, Kaneka is a significant player in the food and nutrition industry. Their extensive product line features dairy products, margarines, fats and oils, whipping creams, fillings, baking essentials (baker's yeast, dough improvers), processed fruits, butter, shortening, cacao butter alternatives, various creams, frozen dough, spices, and antifreeze materials. They also supply pharmaceutical and supplemental nutrition solutions, such as coenzyme Q10, lactic-acid bacteria, and functional foodstuffs, alongside agricultural fertilizers.
www.kaneka.co.jpNo one on the platform currently holds 4118.T.
No tracked institution reports a position in 4118.T as of their last filing.
No one on the platform has traded 4118.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.3% | 4.5% | 5.1% | — | — | — |
| Rev. Growth % | 0.5% | 7.0% | ||||
| Profit Margin % | 3.8% | 3.4% | 3.3% | |||
| Free Cash Flow Margin % | 0.2% | -0.6% | 0.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $862.5B | +6.6% | $492.63 | $400.49–$564.84 | — | 6 |
| 2028 | $886.7B | +2.8% | $504.64 | $432.43–$544.97 | — | 5 |
| 2029 | $904.3B | +2.0% | $552.44 | $496.01–$580.75 | — | 3 |
| 2030 | $879.5B | -2.7% | $617.20 | $583.35–$646.53 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| +1.14% |
| $448.8B |
| — |
| 4272.TNippon Kayaku Co., Ltd. | $2053.50 | +0.10% | $304.6B | — |
| 4617.TChugoku Marine Paints, Ltd. | $3490.00 | +1.60% | $173.2B | — |
Source: Financial Modeling Prep · peers by sector/industry